Femasys is trading at $1.48, down 5.13% in pre-market, with no clear company-specific news explaining the decline. - On October 14, Femasys announced it had doubled actively enrolling FemBloc trial sites to twelve; this positive update does not explain the drop. - Broader risk-off sentiment may be a backdrop: Nasdaq futures were down 1.11% amid inflation and technology-market concerns, but the company announcement does not establish a direct cause.